Patent ID: 7863246
Filing Date: 2011-01-04
Classification: A61K,A61P

Abstract:
1. A method for treating amyotrophic lateral sclerosis (ALS) or enhancing the survival of a motor neuron in a subject diagnosed with a motoneuron disease, the method comprising: administering a vascular endothelial growth factor-A (“VEGF-A”) protein into the cerebrospinal fluid of the subject for up to at least 4 weeks at a dose within a range between 0.01 μg/kg/day and 0.6 μg/kg/day of the subject's body mass, wherein the VEGF-A protein is selected from the group consisting of: VEGF121, VEGF145; VEGF165 and VEGF189, thus treating the ALS disease or enhancing the survival of a motor neuron in the subject diagnosed with a motoneutron disease.